OM
STOK icon

Opaleye Management’s Stoke Therapeutics STOK Stock Holding History

Opaleye Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9M Hold
700,000
– – 2.07% 13
2026
Q1 		$22.8M Buy
700,000
+5,000
+0.7% +$164K 3% 10
2025
Q4 		$22.1M Buy
695,000
+12,983
+2% +$390K 2.91% 7
2025
Q3 		$16M Buy
682,017
+119,897
+21% +$2.05M 2.27% 11
2025
Q2 		$6.38M Buy
562,120
+262,120
+87% +$2.49M 1.29% 18
2025
Q1 		$2M Buy
300,000
+275,000
+1,100% +$2.56M 0.44% 33
2024
Q4 		$276K Buy
+25,000
New +$307K 0.05% 38

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Opaleye Management's STOK Position: Q2 2026 in Review

Opaleye Management held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 700,000 shares worth $22.9M. The position accounts for 2.07% of the portfolio, ranked #13.

Opaleye Management first reported a position in STOK in Q4 2024 and has held it in 7 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Opaleye Management held 700,000 shares of Stoke Therapeutics worth $22.9M as of Q2 2026.
  • Opaleye Management left its Stoke Therapeutics share count unchanged in Q2 2026.
  • Stoke Therapeutics made up 2.07% of Opaleye Management's portfolio in Q2 2026, its #13 holding.
  • Opaleye Management first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.